Introduction
Cystic fibrosis (CF) is a monogenic disease affecting multiple organs. Lung pathology, typified by thick viscous mucous and susceptibility to chronic bacterial infection, is important in determining clinical decline of CF patients. This organ is readily accessible to inhaled medication and consequently antibiotic and mucolytic agents help to abate the disease and increase life expectancy. Both the monogenic cause of CF and the lung's accessibility have made CF a focus of gene therapy for over 10 years. Unfortunately, attempts to replace the defective gene responsible for CF, the CF transmembrane conductance regulator (CFTR) gene with a functional copy have failed to benefit patients in the clinic. The reasons for this are numerous and include immune defences against viral delivery, inefficient non-viral gene delivery, transgene loss and transcriptional silencing. This has motivated clinical researchers to devise new and elaborate ways to overcome these barriers. [1] [2] [3] [4] In contrast to gene replacement, correcting mutations within the endogenous gene offers a more elegant approach to genetic medicine. Precisely repairing a genetic lesion would preserve the regulatory and splicing machinery of a gene. However, this strategy suffers from two weaknesses: (1) inefficient homologous recombination in mammalian cells; and (2) random and potentially mutagenic genomic integration of the targeting construct. 5 Nevertheless, a number of strategies are currently being explored to overcome these barriers (for a recent review see Richardson et al). 6 Our work seeks to exploit these new technologies to target CFTR mutations in lung epithelial cells (or lung progenitor cells). We have focused our efforts on two strategies: (1) short fragment homologous recombination (SFHR) and (2) chimeraplasty.
(1) SFHR utilises the observation that short DNA frag- ments (SDFs) of approximately 500 bp, which are identical in sequence to their target (with the exception of a centrally located mismatch) induce gene repair in mammalian cells. 7 Molecular evidence has recently been presented that this strategy works in cell culture for CF 8 and in vivo in mice. 9, 10 (2)
RNA-DNA oligonucleotides (RDOs, or chimeraplasts) are chimeric oligonucleotides, which consist of both DNA and 2'-O-methyl RNA residues. These fold to form a double-stranded sequence with polythymidine hairpin loops at each end, a central pentameric DNA sequence (containing a single mismatch from their target) and flanking sequences which are DNA:RNA heteroduplexes (see Figure 1 ). These molecules have been used extensively in cell free, cell culture and in vivo systems (refer to Richardson et al 6 for a thorough review of this work). The initial RDO design (such as in Figure 1 ) has been modified in recent studies and the importance of certain structural features dissected.
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Results and discussion
Ideally we wish to target the CFTR gene and demonstrate functional change that may extrapolate to potential clinical benefit. However, assays to detect functional CFTR protein in a background of mutant molecules are very difficult. Therefore to optimise gene correction, we created a reporter system that allows us to measure gene repair directly in living cells. Gene repair reporters have proved effective [11] [12] [13] [15] [16] [17] [18] [19] [20] [21] [22] and we hope that this system will allow application of this technology to living cells (see also Liu et al 14 ) . A single base substitution was introduced into the EGFP gene (from Clontech's pHygEGFP vector (Clontech, Palo Alto, CA, USA)) to create a premature stop codon (GFP W399X) which inactivates the green fluorescence of EGFP. This reporter system allows us to monitor the appearance of green fluorescence as a marker for gene repair. To correct this mutation a 442 bp SDF GFP was made by the PCR and a RDO GFP synthesised (25 bp of homology, Figure 1) .
The GFP W399X reporter plasmid was used to study the gene repair activity of our gene correction molecules (Figure 1) Observing the repair of DNA sequences within plasmids which have been transiently transfected into cells is distinct from repair of the genome. Chromosomal and extrachromosomal repair mechanisms may differ. To address this, we have constructed stable cell lines utilising the hygromycin resistance component of our reporter system. The GFP W399X plasmid was linearised and transfected into cells, which were then subjected to hygromycin selection. Resulting colonies were isolated and the clones expanded and checked for reporter gene expression. Our initial results with these cell lines failed to demonstrate any gene correction using RDO GFP ). We have seen that the larger the SDF GFP the more efficient the gene repair (Table 2) .
We wished to test whether the generally held notion that small molecules (such as oligonucleotides) can be efficiently delivered to the nucleus (but are less stable) was true in our culture system. In addition we were concerned that the observed variation in repair efficiency was related to variation in nuclear delivery of our correc- ). Live cell imaging was performed with both SDF * and RDO * in HT1080 cells during transfection. This also demonstrated that PEI (and also lipid or lipid/peptide) transfections failed to deliver the bulk of the DNA into the nucleus. If the process of recombination is dependent upon the nuclear concentration of targeting molecule, then this delivery problem may be a limiting factor for repair in our system (see Lukacsovich et al 24 for discussion). The observed pattern was the same in each of the cell lines used for the episomal correction study (Table 1) .
To assess the stability of linear SDFs in cell culture, a 1.6 kb linear gene was generated by the PCR. This created a GFP gene under the control of a CMV promoter. After transfection into HT1080 cells, the number of green cells was monitored at different times. A 24-h pre-treatment of cells with trichostatin A (TSA) gave an indication of genomic integration (this histone deactylase inhibitor increases expression of some integrated transgenes: X Nan, personal communication). The results show that after an initial peak of green cells (~12% at 2 days after transfection), transgene expression reduces gradually (~3% at day 7). However, green cells were still observed up to 21 days after transfection (0.15%). At 28 days, the remaining green cells had become sensitive to TSA enhancement, indicative of transgene integration. These data imply that whilst the bulk of the SDFs and RDOs fail to enter the nucleus in our cell culture system, those that are within the nucleus have the potential to remain there for a considerable time.
A number of key safety problems need to be addressed before gene repair can proceed to clinical application. However, an exciting prospect which could bypass some of these hurdles is to exploit stem cells or progenitors cells. If stem cells can be isolated and corrected ex vivo, then re-implanted, a diseased organ could remain corrected for the lifetime of the patient. The successful use of stem cells in replacement gene therapy has already been demonstrated 25 and pluripotent stem cells from bone marrow have been shown to give rise to lung epithelia in the mouse. 26 We are investigating the possibility of using murine airway epithelial stem cell niches, such as those identified by Borthwick et al, 27 as a source of cells for gene repair.
